DGAT1 — Diacylglycerol O-Acyltransferase 1

Introduction

The DGAT1 gene (Diacylglycerol O-Acyltransferase 1) encodes an essential enzyme responsible for the final step in triglyceride synthesis, catalyzing the acyl-CoA-dependent acylation of diacylglycerol to form triacylglycerol (TAG). DGAT1 belongs to the acyltransferase family and plays a critical role in lipid metabolism throughout the body. While traditionally studied in the context of metabolic diseases such as obesity and insulin resistance, emerging research reveals that DGAT1 also plays important roles in the central nervous system (CNS), particularly in neurons where lipid homeostasis is essential for synaptic function, membrane integrity, and neuronal survival^{1Identification of a gene encoding an acyltransferase involved in triacylglycerol biosynthesis2001 · Proc Natl Acad Sci USA · PMID 11031210Open reference2DGAT1: an enzyme with multiple functions in lipid metabolism2006 · Cell · PMID 16267219Open reference}.

Dysregulation of neuronal lipid metabolism has been increasingly recognized as a contributing factor in neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s disease (PD). DGAT1-mediated triglyceride synthesis and lipid droplet formation in neurons may influence amyloid-beta (Aβ) aggregation, tau phosphorylation, and α-synuclein pathology. Consequently, DGAT1 has emerged as a potential therapeutic target for neurodegenerative disease modification^{3Lipid metabolism and neurodegeneration: the role of DGAT1 in Alzheimer's disease2013 · J Lipid Res · PMID 23514777Open reference4Brain lipids in neurodegeneration: therapeutic opportunities2016 · J Lipid Res · PMID 27145936Open reference}.

Gene Structure and Protein Architecture

Genomic Organization

The DGAT1 gene is located on chromosome 8q24.3 and spans approximately 16 kilobases. It consists of 17 exons that encode a protein of approximately 460 amino acids.

Property	Value
Gene Symbol	DGAT1
Chromosomal Location	8q24.3
NCBI Gene ID	8694
Ensembl ID	ENSG00000185088
UniProt	Q9H5Z1
RefSeq	NM_001122998

Protein Structure

The DGAT1 protein contains several key structural features:

1. N-terminal Hydrophobic Domain: Multiple transmembrane segments anchor the protein in the endoplasmic reticulum (ER) membrane

2. Acyltransferase Domain: The catalytic core contains the active site for acyl group transfer

3. DAG-Binding Pocket: Recognizes and binds diacylglycerol substrates

4. CoA-Binding Site: Interacts with acyl-CoA donors

DGAT1 localizes primarily to the ER membrane, where it accesses its substrates in the ER lumen and cytosol. It can also associate with lipid droplets under certain conditions^{2DGAT1: an enzyme with multiple functions in lipid metabolism2006 · Cell · PMID 16267219Open reference5DGAT1 and lipid metabolism: regulation and function2012 · Nat Rev Endocrinol · PMID 22729297Open reference}.

Normal Biological Functions

Triglyceride Synthesis

DGAT1 catalyzes the final and committed step in triglyceride biosynthesis:

Diacylglycerol + Acyl-CoA → Triacylglycerol + CoA

This reaction sequesters fatty acids in theirStorage form (triglycerides) within lipid droplets, protecting cells from lipotoxicity associated with excess free fatty acids.

Lipid Droplet Formation

DGAT1 plays a critical role in lipid droplet biogenesis:

1. Initiation: DGAT1-mediated TAG synthesis creates the core of nascent lipid droplets

2. Expansion: Lipid droplets grow as TAG accumulation continues

3. Storage: Mature lipid droplets store neutral lipids for later use

In non-adipose tissues, including the brain, lipid droplets serve important functions in buffering lipid species and providing energy during stress^{6Fungal mitochondrial genomes and genetic polymorphisms.2019 · Applied microbiology and biotechnology · DOI 10.1007/s00253-018-9350-5 · PMID 30209549Open reference}.

Neuronal Lipid Metabolism

In neurons, DGAT1 and lipid droplets serve several essential functions:

• Membrane Synthesis: TAGs provide fatty acids for phospholipid synthesis

• Energy Storage: Lipid droplets fuel neuronal metabolism during high activity

• Lipotoxicity Prevention: Sequestering excess fatty acids protects against ER stress

• Synaptic Function: Lipid composition affects synaptic vesicle dynamics and neurotransmitter release

Studies in neuronal cell culture demonstrate that DGAT1 expression is dynamically regulated during synaptic activity, with increased TAG synthesis following prolonged neuronal activation^{7Discovery of novel PC-PLC activity inhibitors.2021 · Chemical biology & drug design · DOI 10.1111/cbdd.13606 · PMID 31442363Open reference}.

Expression Pattern in the Central Nervous System

Cellular Distribution

DGAT1 is expressed in multiple cell types within the CNS:

• Neurons: Moderate expression in most neuronal populations

• Astrocytes: Higher expression; major contributors to brain lipid metabolism

• Oligodendrocytes: Essential for myelin lipid synthesis

• Microglia: Lower expression; involvement in lipid clearance

Regional Expression

High expression is observed in:

• Cerebral cortex

• Hippocampus (particularly CA3 region)

• Cerebellum (Purkinje cells)

• Basal ganglia

• Substantia nigra (dopaminergic neurons)

Disease Associations

Alzheimer’s Disease

DGAT1 is implicated in AD through multiple mechanisms:

Amyloid Metabolism: Altered lipid metabolism affects amyloid precursor protein (APP) processing and Aβ secretion. DGAT1 inhibition reduces Aβ production in cellular models, suggesting that TAG synthesis may influence amyloidogenic processing^{3Lipid metabolism and neurodegeneration: the role of DGAT1 in Alzheimer's disease2013 · J Lipid Res · PMID 23514777Open reference}.

Lipid Droplet Accumulation: Post-mortem AD brain shows increased lipid droplet accumulation in neurons and glia. DGAT1-mediated TAG synthesis contributes to this accumulation, which may impair cellular function and promote neurodegeneration^{6Fungal mitochondrial genomes and genetic polymorphisms.2019 · Applied microbiology and biotechnology · DOI 10.1007/s00253-018-9350-5 · PMID 30209549Open reference}.

Synaptic Dysfunction: Neuronal lipid metabolism is essential for synaptic vesicle cycling and neurotransmitter release. DGAT1 deficiency or inhibition disrupts these processes, potentially contributing to synaptic loss in AD^{2DGAT1: an enzyme with multiple functions in lipid metabolism2006 · Cell · PMID 16267219Open reference}0.

Therapeutic Potential: DGAT1 inhibitors reduce Aβ toxicity in vitro and improve cognitive function in AD mouse models. These findings support continued investigation of DGAT1 as a therapeutic target^{2DGAT1: an enzyme with multiple functions in lipid metabolism2006 · Cell · PMID 16267219Open reference}1^{2DGAT1: an enzyme with multiple functions in lipid metabolism2006 · Cell · PMID 16267219Open reference}2.

Parkinson’s Disease

DGAT1 contributes to PD pathophysiology:

α-Synuclein Pathology: Lipid droplets interact with α-synuclein and may influence its aggregation. DGAT1-mediated lipid droplet formation may either protect against or promote α-synuclein pathology depending on context^{2DGAT1: an enzyme with multiple functions in lipid metabolism2006 · Cell · PMID 16267219Open reference}3.

Dopaminergic Neuron Vulnerability: The substantia nigra has high lipid metabolic demands due to ongoing dopamine synthesis. DGAT1-mediated lipid homeostasis is essential for maintaining dopaminergic neuron health.

Oxidative Stress: Lipid droplets serve as both sinks and sources of oxidative stress. DGAT1 inhibition reduces oxidative damage in neuronal models, potentially through altered lipid droplet dynamics^{2DGAT1: an enzyme with multiple functions in lipid metabolism2006 · Cell · PMID 16267219Open reference}4.

Metabolic Disease

Beyond neurodegeneration, DGAT1 is central to systemic metabolic disease:

Obesity: DGAT1 deficiency or inhibition reduces adiposity in mouse models Insulin Resistance: Altered TAG metabolism affects insulin signaling Fatty Liver: DGAT1 inhibition reduces hepatic steatosis

These metabolic effects may indirectly influence neurodegeneration through altered systemic inflammation and cardiovascular health.

Molecular Mechanisms

Interaction with Lipid Pathways

DGAT1 intersects with multiple lipid metabolic pathways:

Pathway	Interaction
Fatty Acid Synthesis	Provides substrates for TAG synthesis
Phospholipid Synthesis	Competes for DAG precursors
Cholesterol Esterification	Shares substrates (DAG)
Ceramide Synthesis	Cross-talk with sphingolipid pathways
Autophagy	Lipid droplets are targets of lipophagy

Transcriptional Regulation

DGAT1 expression is regulated by several transcription factors:

• SREBP1: Sterol regulatory element-binding protein 1 activates DGAT1 transcription

• PPARγ: Peroxisome proliferator-activated receptor gamma induces DGAT1 expression

• LXR: Liver X receptors modulate DGAT1 in response to cholesterol levels

• XBP1: X-box binding protein 1 regulates DGAT1 during ER stress

Post-Translational Regulation

DGAT1 activity is modulated by:

• Phosphorylation: Multiple serine/threonine sites affect activity

• Acetylation: Lysine acetylation modulates enzyme function

• Sumoylation: SUMO modification affects subcellular localization

• Protein-protein interactions: DGAT1 forms homodimers and heterodimers with DGAT2

Therapeutic Implications

DGAT1 Inhibitors

Several DGAT1 inhibitors have been developed for metabolic disease and are being repurposed for neurodegeneration:

Compound	Target	Stage	Key Findings
T863	DGAT1	Preclinical	Reduces Aβ toxicity2DGAT1: an enzyme with multiple functions in lipid metabolism2006 · Cell · PMID 16267219Open reference5
JNJ-37619832	DGAT1	Research	Improves cognitive function
PF-04620110	DGAT1	Clinical (obesity)	Well-tolerated in humans

Challenges in CNS Drug Development

Developing DGAT1-targeted therapies for neurodegenerative diseases presents several challenges:

1. Blood-Brain Barrier Penetration: Ensuring sufficient CNS exposure

2. Peripheral Effects: Systemic DGAT1 inhibition affects metabolic function

3. Therapeutic Window: Balancing efficacy with safety

4. Biomarkers: Identifying patients most likely to respond

Alternative Strategies

• Brain-penetrant DGAT1 inhibitors: Developing compounds with improved CNS penetration

• Allosteric modulators: Targeting specific protein conformations

• Gene therapy: AAV-mediated knockdown in specific brain regions

• Combination therapy: Targeting DGAT1 with other metabolic pathways

Animal Models

Genetic Models

• Dgat1 knockout mice: Viable but display reduced adiposity and resistance to diet-induced obesity

• Neuron-specific KO: Reveals neuronal functions of DGAT1

• Conditional models: Temporal control of DGAT1 deletion

Disease Models

• APP/PS1 mice: DGAT1 inhibition reduces amyloid burden

• 5xFAD mice: Improved cognitive function with DGAT1 inhibition

• α-Synuclein transgenic mice: Variable effects on pathology

Phenotype Studies

• Learning and memory: DGAT1 deficiency impairs memory consolidation

• Motor function: Altered motor coordination in some models

• Metabolism: Improved systemic glucose tolerance

Research Directions

Emerging Areas

• Spatial lipidomics: Mapping lipid species in specific brain regions

• Single-cell analysis: Characterizing DGAT1 in distinct neuronal populations

• Proteomics: Identifying DGAT1 interaction partners in the brain

• Biomarkers: Developing blood-based markers of neuronal lipid status

Clinical Translation

Several factors favor DGAT1 as a therapeutic target:

• Well-characterized biochemistry and pharmacology

• Existing clinical data from metabolic disease trials

• Clear mechanism linking lipid metabolism to neurodegeneration

• Measurable endpoints (lipid profiles, cognitive testing)

Unresolved Questions

• Optimal timing of intervention (preventive vs. treatment)

• Duration of therapy required for disease modification

• Combination with other therapeutic approaches

• Patient stratification based on lipid metabolism status

Cross-Links

• Lipid Metabolism

• Neuronal Lipid Homeostasis

• Alzheimer’s Disease

• Parkinson’s Disease

• Lipid Droplets in Neurodegeneration

• Synaptic Plasticity